Clinical Trial
OVERTURE Phase 3: Gamma Sensory Stimulation for Alzheimer's Disease (NCT05637801)
ClinicalTrials.gov4/18/2026·04/18/26🌐 USA
Summary
Phase 3 trial of Cognito Therapeutics' Spectris wearable (40Hz gamma light and sound, 1 hour/day) in 550 early Alzheimer's patients over 18 months. Primary endpoint: CDR-SB cognitive score change. Follows Phase 2 results showing amyloid and tau reduction.
Why it matters
Positive Phase 3 results would make Spectris the first non-pharmacological Alzheimer's disease-modifying therapy — a landmark outcome for the entire neurotech field.
#Alzheimers#BCI#Neurostimulation#Phase 3
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in